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Abstract
Background: The participant information sheet (PIS) provided to potential trial participants is a critical part of the
process of valid consent. However, there is long-standing concern that these lengthy and complex documents are
not fit-for-purpose. This has been supported recently through the application of a performance-based approach to
testing and improving readability called user testing. This method is now widely used to improve patient medicine
leaflets - determining whether people can find and understand key facts. This study applied for the first time a
controlled design to determine whether a PIS developed through user testing had improved readability over the
original, using a sheet from a UK trial in acute myeloid leukemia (AML16).
Methods: In the first phase the performance of the original PIS was tested on people in the target group for the
trial. There were three rounds of testing including 50 people in total - with the information revised according to its
performance after each of the first 2 rounds. In the second phase, the revised PIS was compared with the original
in a parallel groups randomised controlled trial (RCT) A total of 123 participants were recruited and randomly
allocated to read one version of the PIS to find and show understanding of 21 key facts.
Results: The first, developmental phase produced a revised PIS significantly altered in its wording and layout. In
the second, trial phase 66% of participants who read the revised PIS were able to show understanding of all
aspects of the trial, compared with 15% of those reading the original version (Odds Ratio 11.2; Chi-square = 31.5 p
< .001). When asked to state a preference, 87.1% participants chose the revised PIS (Sign test p < .001).
Conclusions: The original PIS for the AML16 trial may not have enabled valid consent. Combining performance-
based user testing with expertise in writing for patients and information design led to a significantly improved and
preferred information sheet. User testing is an efficient method for indicating strengths and weaknesses in trial
information, and Research Ethics Committees and Institutional Review Boards should consider requesting such
testing, to ensure that PIS are fit-for-purpose.
Background
There have been two areas of recent activity with
regards to clinical trials that might be seen to be in
opposition. On the one hand in some countries there
has been a governmental drive to increase trial activity,
in both the number of trials being conducted and the
proportion of patients taking part [1]. On the other
hand there have been increasing concerns expressed
about the conduct of trials, in relation to participant
safety (particularly in Phase 1 trials) and the process and
quality of informed consent. These concerns were
increased and articulated strongly following the 2006
TGN1412 trial incident at Northwick Park, London, in
which six healthy volunteers became seriously ill [2] and
in the high-level reports that followed [3-6]. The reports
were consistently critical of the inadequacies of informa-
tion giving and the consent process in trials.
In many countries participant consent to clinical
research, including trials, is based on two forms of infor-
mation provision: a written Patient Information Sheet
(the PIS); and spoken information, usually from a clini-
cian. Research has documented the patchy quality of
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patients’ understanding at the end of a trial have found
sub-optimal comprehension, such as one in five partici-
pants not knowing the name of the medicine being tested
[7] and similar proportions not knowing that they could
withdraw at any time [8,9]. These findings are confirmed
by a systematic review of communication and informed
consent in cancer trials [10] in which aspects such as
treatment risks and benefits and the right to withdraw
consent were found to be not well understood. The
review concluded that ‘patients do not appear to be ade-
quately informed’ (p.304). In two observational studies of
patients being recruited to trials key aspects were missing
from spoken information provided by clinicians and par-
ticipants’ understanding of the trial (which was some-
times erroneous) was not checked or corrected [11,12].
A lack of participant knowledge might result from the
difficulty in understanding complex information, such as
randomization [13], or because the PIS is poorly written
o rt o oc o m p l e x .T h el e v e lo fl i t e r a c yr e q u i r e dt or e a d
the PIS is often too high for the general population
[14,15]. Poor information provision may particularly
affect older patients and those with fewer years of edu-
cation [16].
Research into the quality of PIS has used either a
checklist method - looking for the presence of features
that might enhance or inhibit reading - or readability for-
mulae, such as the Simple Measure of Gobbledygook
(SMOG) or Flesch-Kincaid [17-19] - as indicators of
readability. These methods mostly concentrate on word
and sentence length and disregard layout, which may be
an influence on readability [20], and they offer a hypothe-
tical rather than an actual measure of readability. At best
they provide only a partial indication of a document’s
readability and, given the important elements of a docu-
ment that they do not measure, they might be seen to
mislead.
Ancker and colleagues [21] argue that a PIS should be
analyzed according to its performance, rather than on a
number obtained from a readability formula. We
recently adopted a method of performance-based testing
- user testing - to assess the ability of three PIS to
inform people from the target group for the trial
[22-24]. The study findings were consistent: the existing
sheets (which had been approved by NHS research
ethics committees) were flawed in their ability to allow
people to find and understand important aspects of the
trial in relation to safety, efficacy, consent and practical
details. In each of the three studies the PIS had both its
layout and wording significantly revised and further user
testing revealed improvements in its performance.
However, weaknesses of this previous research were
twofold: the studies included small sample sizes, and the
study design (that is, serial testing and refinement)
allowed the possibility that (although the cohorts were
matched by age and education) better performance of
the PIS was due to sample characteristics and not
improvements in the sheet itself. The study reported
here aimed to overcome these methodological weak-
nesses to give an estimate of the size of effect of
improving the readability of a trial PIS, in this case the
PIS used in a recent trial of treatments in AML16. The
study comprised two phases: (1) a developmental phase
and (2) a trial phase.
Developmental phase: method
Design
An independent groups design was used, with each par-
ticipant seeing only one version of the information.
Participants
Fifty members of the public were recruited using local
publicity (flyers and newspaper adverts) to take part in
readability studies. Participants were adults aged 55 and
over, to mimic recruitment to the actual AML16 trial.
Exclusion criteria were: having taken part in any medi-
cine trial or readability study in the previous six months;
close personal experience of leukemia; healthcare profes-
sionals. We ensured that each round of ten participants
had a similar profile in terms of two likely influences on
testing, age and education.
Tested materials
The first PIS tested was the or i g i n a lA M L 1 6t r i a lP I S ,
comprising ten pages of single-sided A4 paper and con-
taining 3,200 words of text (see Figure 1 for an example
section) was obtained from the AML trials website
(http://www.aml16.bham.ac.uk). We contacted the
authors to inform them of the proposed study, and
asked for confirmation about how it was presented to
potential participants. Before testing, all content identi-
fying individuals or organizations was replaced with
pseudonyms.
The second tested material was a first revision of the
AML16 trial sheet, retaining its meaning but with
revised layout, appearance, structure and wording -
informed by the results from the first round of testing.
In the third round of testing a second revision of the
trial sheet, informed by the results from the second
round of testing, was evaluated.
Outcomes
Participants’ ability to find 21 key points of information
in the sheets, and then show their understanding of
each of those points (see Table 1). The 21 items were
drawn from four categories that apply to trials of any
phase: the nature and purpose of the trial (4 questions);
the process and meaning of consent (4 questions); trial
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tested medicine (7 questions).
The authors independently selected the key points for
questions, based on the pre-defined categories, with any
differences reconciled by consensus, and the questionnaire
was then written. Questions were arranged so that their
order did not correspond with the order of the informa-
tion in the sheet. During testing, each of the 21 items was
scored for finding information (yes or no) and, if found,
scored for understanding (yes or no).
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PATIENT INFORMATION SHEET 2  
& CONSENT FORM 2

 
1.  Study title 
 
 AML-MDS  Trial 
 
 
2.  An invitation to participate in the AML-MDS trial 
 
You are being invited to take part in a clinical trial.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.   
Please take time to read the following information carefully and discuss it with others 
if you wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
Thank you for reading this information.  If you decide to take part you will be given a 
copy of this information sheet and your signed consent form. 
 
 
3.  What is the purpose of the AML-MDS trial? 
 
Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are malignant 
conditions of the bone marrow.  They both result in failure of the bone marrow to 
manufacture enough blood cells (red cells, white cells and platelets), because the 
marrow contains too many leukaemia cells.  The details of these conditions will have 
been explained to you by your Haematology Team.  There are two approaches to 
treatment and these will be explained to you by your treatment team. The first 
comprises between 2 and 4 courses of intensive chemotherapy which are given 4-6 
weeks apart usually as an inpatient.  The aim of treatment is to kill off the leukaemia 
cells and allow the marrow to work normally which is called disease remission, and 
is expected to happen after the first or second treatment course.  Because there is a 
risk of the disease coming back a further 2 or 3 courses of treatment are given. This 
approach has risks associated with it. This approach may or may not be considered 
suitable for you. 
 
The second approach is to use drugs to control the leukaemia cells in the bone 
marrow rather than to try to get rid of them completely. This approach is less 
intensive and some of the treatments can be given by mouth and taken as a 
outpatient. The chances of the disease going into complete remission are lower, but 
much less time in hospital is required. 
 
For some patients, particularly those who are less fit or have other medical 
conditions, this may be thought to be a better approach. Which treatment approach 
is adopted for you will be decided after you have had a discussion with your doctor. 
Figure 1 Example page of the original AML16 Participant Information Sheet.
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information sheets were recorded in the second part of
the interview, as was the time taken to read the infor-
mation sheet and the time taken for the structured user
testing questions.
Procedure
This phase comprised 3 stages:
1. Testing of the original information sheet. The
information was tested using participants who were
instructed to imagine receiving treatment for leuke-
mia and being asked to take part in a trial to test
different drug treatments. They were posted the
sheet so that they received it at least 24 hours before
testing and were asked to read it carefully (and note
how many minutes it took them to read it). When
they attended for testing they were given a chance
to read it once more (with the reading time
recorded) and were left alone to do so. Then each of
the 21 user test questions was put in turn and the
participant was asked, first, to find the answer in the
sheet and, second, to give their answer and, where
required, to explain what the information meant.
The interviewer judged if the participant had
demonstrated understanding by their answer to each
Table 1 Information finding and understanding results from the trial phase
Original version
(n = 55)
Revised version
(n = 61)
Found If found,
understood
Found If found,
understood
Nature and purpose of the trial
Q4 What sort of patient is being offered ‘non-intensive’ treatment? 45 45 58 58
Q14 What is this trial trying to find out? 24 18 54 49
Q15 How will it be decided which patients in the trial receive which treatment? 52 52 61 61
Q20 A patient could get 1 of 4 different treatments within the trial. What are the 4 different
treatments?
55 52 60 59
Process and meaning of consent
Q2 Suppose you decided to take part in the trial but later changed your mind. Would you have
to give a reason?
55 55 59 59
Q8 Suppose you take part and are harmed by the trial. What can you do? 54 54 60 60
Q16 What happens to the information collected about you as part of the trial? 55 54 61 60
Q17 Suppose you decide not to take part in the trial and receive the standard treatment. What
medicines would you be given?
37 36 58 58
Trial procedures
Q1 If you need to contact the Haematology Unit at the hospital, what number should you use? 49 47 61 61
Q3 Suppose you receive the drug Trisenox in the trial. How and when would it be given to
you?
55 55 61 61
Q7 What does the sheet say about the blood tests you would need to have if you took part in
the trial?
35 34 58 57
Q10 During the trial you may need to receive transfusions. Of what? 55 54 61 61
Q12 When you receive any of the treatments in this trial, how far apart are the courses of
treatment?
54 53 61 61
Q21 If you don’t take part in the trial and receive low dose Cytarabine as the ‘standard
treatment’. How is it given to you and how often?
53 49 61 60
Safety and efficacy of the medicine
Q5 What should you do to try to stop yourself getting a cold or infection while in this trial? 53 52 60 60
Q6 Which parts of the body are most likely to be affected by side effects of the medicines in
this trial?
54 54 61 60
Q9 The medicine Mylotarg can cause jaundice. What does the information say about jaundice
and what you should do?
54 54 60 60
Q11 What does the sheet say about contraception while taking part in this trial? 55 55 58 58
Q13 What does the information say about driving to and from the hospital for treatment? 55 55 60 60
Q18 After each course of treatment the doctor may want to examine your bone marrow. Why? 45 41 60 59
Q19 Imagine you are taking part in the trial and you get an infection. What should you do? 52 51 60 60
Total items NOT found 109/
1155
28/
1281
Total items found but NOT understood 26 11
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through later discussion among the interviewers and
PK, by using the interview transcript. No upper time
limit was placed on answering each question and the
interviewer moved on to the next question when the
participant provided an answer, or if the participant
gave up and requested to move on, or when it
became clear that they could not find the answer.
After the 21 structured questions participants were
asked for their general impressions of the sheet, with
particular focus on the appearance, wording, print
size, headings and organization of information. Inter-
views were audio recorded and transcribed.
2. Re-wording and re-design of the Information
Sheet. Revision of the information was based on
three sources: participants’ user test questionnaire
data and their opinions; good practice in information
wording and design [24]; the authors’ experience and
expertise in information writing and design. Care
was taken to retain the original meaning of the
information, and no information was removed,
except in the case of repetition.
3. Testing of the revised Information Sheet (as per
stage (1), followed again by participants’ evaluative
comments.
Data analysis
Data analysis looked at: the scores for each of the 21
questions to determine how many participants could
find and then understand the answer to each question
and could at least eight of ten participants do so, to
match European Commission legislative thresholds for
licensed medicine leaflets [25]; how many participants
could answer all of the 21 questions correctly (that is,
score a clear round); and participants’ evaluative com-
ments after the formal questioning.
Results
Testing of the original PIS was conducted on 20 partici-
pants during March 2009, following 4 pilot interviews,
using the 21 item user test questionnaire as reported in
Table 2. Among the 21 questions, 3 questions (7, 17,
21) had significant problems, with fewer than 16 of 20
participants being able to find the answer and show
understanding. Only 3 of the 20 participants (15%) were
able to find and show understanding for all 21 questions
(clear round). Problems identified were that some
aspects of the trial were not explained clearly (for exam-
ple, participants struggled to understand whether there
were three, four or five arms to the trial) or the sheet
used technical language that participants found difficult.
In addition, the PIS was densely printed and text heavy.
The layout was hard to follow; for example, sub-sections
were not well indicated and the hierarchy of headings
was unclear.
Testing of the first revised version was conducted on
10 participants during April 2009, following 4 pilot
interviews. Of the 21 questions, 1 question scored fewer
than 8 out of 10 participants finding and showing
understanding. Four of the ten participants scored a
clear round (40%). Participants were experiencing some
problems with understanding the allocation of treat-
ments and finding information about data storage. As a
result, testing was halted after 10 participants and
changes were made to the sub-headings. For example,
the sub-heading ‘Will my taking part in this trial be
kept confidential?’ was changed to ‘What will happen to
information about me collected during the trial?’
Testing of the second revised version was conducted
on 20 participants in April and May 2009. Participants
were better able to find and understand information in
the PIS; interview times were reduced and participants’
evaluations of the PIS were more positive. On only 1 of
t h e2 1q u e s t i o n sd i df e w e rt h a n1 6o u to f2 0p a r t i c i -
pants find and show understanding of the information.
Ten of the 20 participants scored a clear round (50%).
We now had a revised version of the PIS which user
testing suggested had improved readability. The second
phase compared the original sheet with the improved
sheet in a controlled study to determine whether this
confirmed the difference and to estimate the size of
effect.
Trial phase: method
Design
A controlled trial design was used, featuring parallel
groups, two arms, with stratified, random allocation by
individual.
Participants
A total of 123 members of the public were recruited
using local publicity (flyers and newspaper adverts) to
take part in readability studies. As for the developmental
phase, participants were adults at least 55 years old cho-
sen to mimic recruitment to the actual AML16 trial,
and the exclusion criteria were also the same.
Allocation
Participants were allocated to one of two groups (origi-
nal or revised PIS) by random number sequence with
permuted blocks of four. Allocation was stratified
according to two factors that may impact on the ability
to find and understand information during testing: age
(55 to 69; 70+); and education (completing education at
16 or under; completing at 18 or equivalent; being a
higher education graduate). After consent was taken, the
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the allocation.
Tested materials
Two PIS were tested: (1) the original AML16 trial parti-
cipant information sheet, as described above (see Figure
1); and (2) a revised version of the AML16 trial sheet,
developed and tested as described above, retaining its
meaning but with revised format, appearance and word-
ing (for examples see Figures 2 and 3).
The revised version was printed double-sided on two
sheets of A3 paper, then folded to form a birthday card
style booklet of A4 size. Text was printed using Lino-
type Frutiger Next black font and blue headings were
used to contrast with the body text. Page numbers were
inserted, as were clear sub-headings (denoted by use of
larger, bold text). Bullets and numbers were used for
lists. A contents list was placed on the front page, as
well as a headline section summarizing key points in the
sheet. The main text of the sheet was divided into eight
sections (Why we are doing this study; Why am I being
asked to take part?; What do I need to know about the
medicines used in this study?; What will I need to do if
I take part?; Possible side effects; Possible benefits and
disadvantages of taking part; More information about
taking part; Contacts for further information).
Changes to the wording included shortening sentences
and paragraphs, as well as replacing difficult or technical
words with a lay alternative. Examples include: from
‘disease going into complete remission’ to ‘getting rid of
the leukemia’; from ‘nausea and vomiting’ to ‘feeling and
being sick’;a n df r o m‘...doctor will check your blood
chemistry’ to ‘...doctor will do blood tests’.
When technical terms were required in order to be
precise, we first used a lay alternative and followed it
with the original term in parentheses. Examples include:
‘given slowly into a vein (intra-venous infusion)’;a n d
‘injection under the skin (sub-cutaneous)’.
We also gave greater prominence to the contact
names and telephone numbers and placed them on both
the first and last pages.
Outcomes
As for the developmental phase, we were interested in
participants’ ability to find 21 key points of information
in the sheets, and then convey their understanding of
each of those points (see Table 1). The primary outcome
measure was the proportion of participants who could
find and understand all 21 aspects.
Participants’ preferences for one of the two participant
information sheets were recorded, as was the time taken
to read the information sheet and the time taken to
complete all the structured user testing questions.
Procedure
The procedure followed that used for the developmental
phase, but with two additions. First, after the recruit-
ment phone call to a participant, the researcher phoned
a telephone randomization center to receive the alloca-
tion. The PIS was then posted, ensuring that the partici-
pant would receive it at least 24 hours before testing.
Second, at the end of testing, participants were shown
the PIS version that they had not been tested on, and
were asked to read it briefly. They were asked to state
which of the two versions they preferred and why.
Sample size and data analysis
We based the sample size of the trial phase on the
proportion of participants who would be able to find
and understand answers to all 21 questions. Based on
data from the developmental phase, we estimated that
the revised PIS would result in twice as many partici-
pants having a clear round (estimated proportions
were 25% for the original and 50% for the revised ver-
sions) - a difference we considered meaningful in
terms of valid consent. With 90% power a sample size
of 116 participants would be needed at the p <. 0 1
level of probability.
The variables of interest were: the number of partici-
pants having a clear round (that is, finding and under-
standing all 21 answers); the mean number of items
either not found or not understood; the mean total
reading time; the mean time taken for the 21 structured
Table 2 Participant characteristics in the trial phase
Original PIS
a Revised PIS Original PIS Revised PIS
Sex 19 m/43 f 23 m/38 f 18 m/37 f 23 m/38 f
Age Mean 63.9 years (IQR
b
58-65)
Mean 65.7 years (IQR
62-68)
Mean 64.1 years (IQR
58-66)
Mean 65.7 years (IQR
62-68)
Highest educational attainment (1 =
completed by 16;
2 = by 18 or equivalent;
3 = graduate)
1=3 1
2=1 8
3=3
1=3 1
2=1 3
3=1 7
1=2 6
2=1 7
3=1 2
1=3 1
2=1 3
3=1 7
n=6 2 n=6 1 n=5 5 n=6 1
Randomized (n = 123); interviewed (n = 116)
aPIS, patient information sheet;
bIQR, Inter-quartile range,
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AML-MDS Clinical Trial
Patient Information Sheet 
for Non-Intensive Treatment
National Research Institute For Cancer 
Acute Myeloid Leukaemia and High Risk MDS Trial 
How to contact us
If you have any questions 
about this study, please talk 
to your doctor at
Haematology Unit
Newland Hill NHS 
Foundation Trust
Newland Hill Hospital
London NW16 7BJ
Tel: 01234 149 688
Contents
1 Why we are doing this 
study.
2 Why am I being asked to 
take part?
3 What do I need to know 
about the medicines used in 
this study?
4 What will I need to do if I 
take part?
5 Possible side effects.
6 Possible beneﬁ  ts and 
disadvantages of taking 
part.
7 More information about 
taking part.
8 Contacts for further 
information
We invite you to take part in a research study 
•  Before you decide whether to take part, it is important for you 
to understand why the research is being done and what it will 
involve.  
•  Please take time to read the following information carefully. 
Discuss it with friends and relatives if you wish. Take time to 
decide whether or not you wish to take part.
•  You are free to decide whether or not to take part in this 
research study. If you choose not to take part, this will not 
affect the care you get from your own doctors.
•  Ask us if there is anything that is not clear or if you would like 
more information. 
•  Thank you for reading this information.  If you decide to take 
part you will be given a copy of this information sheet and 
your signed consent form. 
Important things that you need to know
•  We want to ﬁ  nd out the best non-intensive treatment for 
Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS).
•  We are testing three new medicines, which are Clofarabine, 
Mylotarg and Trisenox, and an existing medicine, which is 
Cytarabine.
•  The medicines are given separately or together with other 
medicines, and this trial has four different groups or treatment 
options.
•  Regardless of which treatment group you are in, you will 
receive four courses of treatment. 
•  Like all medicines used to treat leukaemia, the medicines used 
in this trial can have side effects. 
•  The trial ﬁ  ts into your normal treatment, so there are no extra 
hospital visits.
•  You can stop taking part in the study at any time, without 
giving a reason.
Newland Hill
Figure 2 Page 1 of the revised AML16 Participant Information Sheet.
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1  Why we are doing this study
This trial is for people with one of 2 types of 
cancer of the bone marrow:
•  Acute Myeloid Leukaemia (AML)
• Myelodysplasia  (MDS)
The trial will compare one of the standard non-
intensive treatments (Low Dose Cytarabine) with 
three other medicines. It will also look at any side 
effects of the medicines.
What happens in these cancers?
In both types of cancers, the bone marrow cannot 
make enough blood cells (red cells, white cells and 
platelets). This is because the marrow contains 
too many leukaemia cells. If you want to know 
more about these illnesses, talk to people in your 
Haematology team. 
What are the two main 
types of treatment?
There are two main ways of treating AML in 
older patients. The ﬁ  rst of these (intensive 
treatment) is with medicines (chemotherapy). 
The idea of this treatment is to get rid of the 
leukaemia completely. The second way (non-
intensive treatment) is also to use medicines 
(chemotherapy), but which have a lower chance of 
getting rid of the leukaemia. This is usually suitable 
for patients who may not be able to withstand the 
more intensive treatment, or who do not want it. 
Patients having non-intensive treatment do not 
need to be in hospital so often.
The aim of both intensive and non-intensive 
treatments is to kill the leukaemia cells and allow 
the bone marrow to work normally again. This 
stage is called ‘disease remission’. The two types 
of treatment are:
•  Intensive Treatment - involves coming into 
hospital 2 to 4 times and having chemotherapy 
by injection. This is usually as an in-patient. This 
approach usually leads to disease remission, but 
has some risks. 
-  It is suitable for people who are more ﬁ  t. 
•  Non-Intensive Treatment - involves less time in 
hospital. Some of the medicines can be taken by 
mouth and as an out-patient. The medicines are 
used to control the leukaemia cells in the bone 
marrow, rather than to try to get rid of them 
completely. This means it is less likely to cause 
complete disease remission.
-  It is more suitable for people who are less ﬁ  t, 
or have other illnesses.
If you want to know more about these two 
treatments, talk to people in your Haematology 
team. 
Your doctor has discussed these two treatments 
with you. As a result it was decided that you will 
have the ‘non-intensive’ treatment. 
If you decide not to enter this trial, you are likely 
to receive the standard non-intensive treatment, 
which is up to four courses of Low Dose Cytarabine 
(see Section 4), or a medicine called Hydroxyurea 
(given by mouth).
The rest of this leaﬂ  et is about the non-intensive 
treatment given within the trial. 
2 
Why am I being asked 
to take part?
Your doctor has found that you have AML or 
MDS. This needs treatment with non-intensive 
chemotherapy. Treatments for patients getting 
non-intensive chemotherapy need to be improved. 
New treatment options have become available 
which will be tested in this trial’.
3  
  What do I need to know 
about the medicines 
used in this study?
One of the standard treatments at the moment is a 
medicine called Cytarabine. It is given in low doses. 
This treatment is called ‘Low Dose Cytarabine’.
This research trial is aimed at testing three new 
medicines, used together. The three medicines are:
• Clofarabine
• Mylotarg
• Trisenox.
These medicines have already been given to 
patients separately. 
Figure 3 Page 3 of the revised AML16 Participant Information Sheet.
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Page 8 of 12user testing questions; and participants’ preferences for
the PIS version.
Research ethics
Approval to conduct both phases of the study was
granted by the University of Leeds, School of Healthcare
Research Ethics Committee in May 2009.
Trial phase: results
Participants
A total of 123 people were randomized, of whom 116
were interviewed. Two were withdrawn due to protocol
violation (one was under 55 years of age; the other was
posted the wrong PIS version) and five did not attend
(three were unwell on the day; one found the PIS upset-
ting and did not want to be interviewed; one did not
attend and could not be contacted). All seven partici-
pants not interviewed, had been randomised to the ori-
ginal PIS group. Hence the analyses are based on 116
interviewed participants, as guided by the sample size
calculation (55 in the original group and 61 in the
revised group), see Figure 4.
Following three pilot interviews, 116 participants were
interviewed during June to August 2009.
Finding and understanding all 21 answers (clear round)
Eight participants (14.5%) in the original PIS group were
able to find and understand all 21 answers, whereas 40
participants (65.6%) in the revised PIS group were able
to do so. The difference is statistically significant.
Original 8/55
Revised 40/61
Chi-square = 31.5; P < .001; Odds Ratio = 11.2
Finding and understanding scores
Participants’ ability to find answers in the PIS to the
questions (see Table 1) was associated with the ver-
sion they had read. On average those reading the ori-
ginal version could not find 1.9 items (standard error
(SE) 0.2; range 0 to 6); in the revised version group
the mean was 0.4 items (SE 0.2; range 0 to 10). The
difference (mean 1.5; 95% Confidence Intervals (CIs)
1.0 to 2.0) is statistically significant (F = 4.73; p =
0.032).
   
Randomised 
(n= 123)
Allocated to original PIS
(n= 62)
Received allocated intervention 
(n = 60)
Did not receive allocated 
intervention (n= 2):
(n= 1 recruited in error; n= 1 
posted wrong PIS).
A
l
l
o
c
a
t
i
o
n
Allocated to revised 
PIS
(n= 61)
Received allocated 
intervention (n= 61)
I
n
t
e
r
v
i
e
w
Interviewed (n= 55)
Not interviewed (n= 5):
(n= 3 unwell; n= 1 unwilling to 
be interviewed; n= 1 did not 
attend)
Interviewed (n= 61)
Not interviewed (n= 0)
Figure 4 Trial flow diagram.
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they had found. Their ability to understand answers to
questions was not associated with the sheet they had
read. In the original version group they could not
understand 0.3 items (SE 0.1; range 0 to 3), whereas in
the revised version group they could not understand 0.2
items (SE 0.1; range 0 to 3). The difference (0.1; 95%
CIs -0.1 to 0.4) is not statistically significant (F = 1.92; p
= 0.17).
Reading and question times
Participants’ reading times were calculated by adding
their self-recorded home reading time and their reading
time before testing (when applicable). All participants
reported reading the sheet at home and had recorded
their reading time, which ranged from 10 to 90 minutes.
A total of 48 participants (41.4%) chose to read the
sheet again immediately before testing (and this addi-
tional reading time ranged from 2 to 25 minutes). Total
reading time did not vary according to group (original
version 27.6 minutes, range 14 to 90, SE 1.5; revised ver-
sion 28.4 minutes, range 11 to 79, SE 1.7; F = .030,
p = .86).
The time taken to complete the 21 structured user
test questions varied greatly among the participants and
also varied according to allocation. Participants reading
the original PIS needed 42.4 minutes (range 16.0 to
72.3; SE 1.7) whereas those reading the revised PIS
needed 26.4 minutes (range 13.4 to 58.2; SE 1.3). The
mean difference of 16.1 minutes (95% CIs 12.0 to 20.2)
was statistically significant (F = 60.1; p < .001).
Sheet preference
Participants’ stated preference also showed a significant
difference between the two versions. Fifteen participants
(12.9%) preferred the original version, whereas 101 par-
ticipants (87.1%) preferred the revised (Sign test p <
.001).
Discussion
User testing of the AML16 participant information sheet
showed that it performed sub-optimally. Participants
could not find or took a long time to find some of the
information, but when information was found, it was
almost always understood. Only a small minority of par-
ticipants were able to find and show understanding of
all aspects of the AML16 trial from the original version
of the PIS. The revised version performed much better.
Time taken in interviews was much shorter, illustrating
the difficulty faced in finding answers by those in the
original version group, and almost two-thirds of partici-
pants were able to find and show understanding of all
aspects of the AML16 trial. When asked to compare the
two sheets and state a preference, almost all participants
preferred the revised version.
The sheet had been significantly revised during the
developmental phase, by noting its performance during
user-testing, and re-writing and re-designing to address
the problems identified, using good practice in informa-
tion design and clear writing. The contribution of user-
testing as a developmental tool appears crucial - for
example, in indicating continued weaknesses and in
confirming when changes to the sheet have had a mean-
ingful effect. These weaknesses could not have been
identified solely through expert review.
The results confirm the pattern reported in three
smaller, uncontrolled studies [22-24]. This study con-
firms that it is possible to improve written trial informa-
tion (both in terms of its ability to inform and its
appeal) by a combination of testing by lay people, along
with the application of clear writing and information
design. There was no difference between the two ver-
sions in the amount of information understood, but
readers first have to locate information in order to
understand it. This finding may indicate the greater con-
tribution made by revision of the structure and layout of
the PIS, as compared to changes in wording. However,
to determine conclusively the relative effects of wording
revisions and design revisions would require a different
study design to that used here.
In several aspects of the study there were significant
differences between what took place and what would
happen to patients actually being asked to consider trial
participation. The participants were members of the
public asked to imagine themselves in a situation, parti-
cipants were able to read the PIS at home before testing,
and finally the user testing interviews took place in a
quiet interview room rather than a busy hospital or
clinic. While these factors may have aided participants
in their reading, it is unlikely to have biased the data in
f a v o ro fe i t h e rv e r s i o n .A l s oi nc o n t r a s tt oa na c t u a l
trial, participants were asked to show an understanding
of the AML16 trial from the PIS alone, without access
to spoken information from a recruiting clinician. It is
unclear whether the presence of a clinician would nar-
row differences between the two versions of the PIS, or
whether clinicians might in fact provide clearer spoken
information when being able to refer to a PIS that was
more clearly written and designed. This would be
worthy of further research.
As mentioned in the introduction Ancker [21] and
others argue that a PIS should be analyzed according to
how it performs, rather than by a number obtained
from a readability formula, a view supported by this
study. US Institutional Review Boards often require a
certain formula score to be obtained before a trial sheet
Knapp et al. BMC Medicine 2011, 9:89
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guage within a document, but they offer very limited
data in terms of which aspects of a document work and
which do not. The user testing scores obtained for the
original AML16 PIS would question whether a partici-
pant in the trial would have been able to give valid or
informed consent, particularly since only one in seven
people could find and understand answers to all
questions.
The study examined participants’ ability to find and
understand written information, rather than test their
willingness to participate in a trial. This study shows
convincingly that a participant dependent only on writ-
ten information would be more able to use it effectively,
when it has been written and designed with its purpose
in mind, as argued by Jefford and Moore [26]. However
the effect on actual trial participants is an important
question. If using improved sheets resulted in increased
trial recruitment rates, this would be both meaningful
and valuable. Thus the effectiveness (and cost-effective-
ness) of improving participant information materials is a
question that requires an answer. A recent systematic
review of interventions to increase trial recruitment
reported that different forms of information had no
impact [27]. What is not clear from the review is
whether enhanced information failed to impact on
knowledge, or whether it did increase knowledge but
failed to change behavior - an important distinction that
deserves clarification.
Conclusions
Combining the use of user testing by lay people with
expertise in writing for patients and information design
resulted in a greater proportion of participants being
able to find and understand information about the trial.
Not only would this impact on the extent to which valid
consent is given, but it may also impact on the recruit-
ment rate and patient behavior within the trial. Research
ethics committees and Institutional Review Boards
should consider requesting user testing to provide assur-
ance that PIS are meeting the needs of people being
recruited to clinical trials.
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